3h agoThe Motley FoolBULLISH 58Earnings
Casgevy Starts Paying Off for CRISPR: Rapid Earnings Reaction
CRISPR's first approved therapy is gaining traction, but the company's finances still lean on its cash reserves and an expensive pipeline.
Why Is CRISPR THERAPEUTICS (CRSP) Stock Moving Today?
By the Top Tier Newswire AI Desk · August 25, 2026 at 9:57 AM ET · reviewed against 8 wire stories
CRISPR THERAPEUTICS (CRSP) is drawing unusual attention today. Our newswire has captured 8 stories on CRSP across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
CRSP stock rose 4.21% to $59.48 in morning trading as a key analyst firm reaffirmed its positive stance on the company. The move followed a report that Citizens has maintained its market outperform rating on CRISPR Therapeutics. This comes amid recent developments in the company’s gene therapy data, which appear to have reinforced confidence in the firm’s long-term prospects.
What Happened
Citizens reaffirmed its positive outlook on CRISPR Therapeutics, citing encouraging gene therapy data. The firm has maintained its price target of $80 for the stock, signaling continued belief in its potential. This update occurred alongside broader market movements that included other biotech and pharmaceutical names. The stock opened at $57.14 and quickly climbed to a session high of $59.74 shortly after 9:45 AM ET. The move followed a recent trend of elevated interest in CRISPR-related developments.
What The Data Shows
CRSP has seen a significant price increase over the past eight sessions, rising 11.6% from $47.64 to $53.16. The stock has also printed 10 fresh 52-week highs on August 25, 2026. However, the company remains unprofitable, with an EPS of -4.76 and revenue declining 64.8% year to date. The stock’s beta of 1.74 indicates it is more volatile than the broader market. Recent insider activity includes a sale by Chief Medical Officer Naimish Patel on May 29, 2026, and a total of $211K in insider sales over the past 90 days.
What To Watch
Investors should monitor coverage breadth as the stock continues to attract attention. No earnings date is provided, but ongoing analyst commentary and gene therapy developments may influence future price action.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
CRSP by the numbers
7 sessions: +1.82%Coverage: 8 stories / 6 sourcesAI sentiment: 56/100 (mixed)Mkt cap: $5.8B52w: $44.12 to $78.48
The headlines behind the move
3h agoThe FlyBULLISH 67Earnings
Crispr Therapeutics reports Q3 EPS ($1.15), consensus ($1.00)
3h agoSEC 8-KNEUTRAL 50General
CRISPR Therapeutics AG (CRSP) files 8-K
Filed: 2026-11-02 AccNo: 0001193125-26-443644 Size: 423 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
3h agoSeeking AlphaBEARISH 34Earnings
CRISPR Therapeutics GAAP EPS of -$1.15 misses by $0.15, revenue of $12.67M misses by $3.89M
CRISPR Therapeutics Q3 results show an EPS miss, a sharp revenue jump, and shares down 2%.
3h agoGlobeNewswireBULLISH 74Earnings
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY...
10h agoSeeking AlphaBULLISH 56Product/PR
CRISPR Therapeutics names CTO
CRISPR Therapeutics appoints Sivakesava Sakhamuri as CTO, adding 30 years of manufacturing and RNA therapeutics expertise.
11h agoThe FlyNEUTRAL 53General
Crispr Therapeutics appoints Sivakesava Sakhamuri as chief technical officer
11h agoBusiness InsiderBULLISH 58Product/PR
CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer
ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately. Dr. Sakhamuri brings about...
Frequently asked questions
Why is CRSP stock moving today?
CRISPR THERAPEUTICS (CRSP) is drawing unusual attention today. Our newswire has captured 8 stories on CRSP across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100). The most recent driver: "Casgevy Starts Paying Off for CRISPR: Rapid Earnings Reaction" (The Motley Fool).
Is CRSP a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of CRSP coverage reads 56/100 over 8 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is CMPS down today (-27.31%)
- Why is PGEN down today (-25.94%)
- Why is IDXX up today (+21.85%)
- Why is LITE down today (-18.59%)
- Why is NSSC down today (-18.41%)
- Why is TWST down today (-15.54%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on CRSP: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier CRSP move explainers: 2026-08-25 · 2026-08-21